## Mankind Pharma Limited (MANKIND) Stock Analysis - December 20, 2024

This report analyzes the provided data for Mankind Pharma Limited (MANKIND) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Field             | Value                     |
|----------------------|--------------------------|
| Symbol              | MANKIND                   |
| Company Name        | Mankind Pharma Limited     |
| Industry            | Pharmaceuticals           |
| Listing Date        | May 9, 2023               |
| ISIN                | INE634S01028              |


**1.2 Market Data:**

| Field                | Value      |
|-----------------------|-------------|
| Last Price            | 2,800.00    |
| Change                | -91.05     |
| % Change              | -3.15%      |
| Previous Close        | 2,891.05    |
| Open                  | 2,907.80    |
| Close                 | 2,805.20    |
| VWAP                  | 2,834.73    |
| Week High             | 2,922.90    |
| Week Low              | 1,851.05    |
| Sector PE             | 54.51      |
| Symbol PE             | 54.51      |


**1.3 Pre-Open Market Data:**

The pre-open market showed a higher opening price (2907.8) than the closing price, suggesting initial buying interest. However, the final price closed significantly lower.

| Price     | Buy Qty | Sell Qty |
|-----------|---------|----------|
| 2,892.05  | 1       | 0        |
| 2,893.00  | 4       | 0        |
| 2,895.00  | 21      | 0        |
| 2,900.00  | 150     | 0        |
| 2,906.00  | 500     | 0        |
| 2,907.80  | 0       | 145      |
| 2,909.95  | 0       | 32       |
| 2,910.00  | 0       | 32       |
| 2,910.15  | 0       | 14       |
| 2,910.90  | 0       | 5        |


**1.4 Delivery Data:**

| Field                     | Value      |
|--------------------------|-------------|
| Quantity Traded           | 671,820    |
| Delivery Quantity         | 278,455    |
| Delivery to Traded Ratio | 41.45%     |


**1.5 Corporate Actions:**

No dividends or other corporate actions are reported in the provided data.


**1.6 Announcements:**

Recent announcements include several Qualified Institutional Placements (QIPs),  "Alteration Of Capital and Fund Raising-XBRL", "Allotment of Securities", and general updates.  These suggest significant capital activity.


**1.7 Financial Results (Last Five Quarters):**

| Quarter      | Income       | Expenditure  | Profit After Tax | EPS     |
|--------------|--------------|---------------|-------------------|---------|
| Q3 FY2025    | 263,550      | 186,505       | 63,443           | 15.04   |
| Q2 FY2025    | 249,809      | 192,072       | 51,349           | 12.09   |
| Q1 FY2025    | 223,654.05   | 169,168.08    | 45,416.97        | 11.34   |
| Q4 FY2024    | 242,579.67   | 184,944.51    | 48,707.33        | 12.16   |
| Q3 FY2024    | 251,146.35   | 189,950.11    | 47,288.44        | 11.80   |


**1.8 Shareholding Patterns:**

Promoter holding has decreased from 76.50% in Q3 FY2024 to 74.87% in Q3 FY2025.  This is a relatively small decrease.


**1.9 Board Meetings:**

Several board meetings have been held, including those to approve financial results and fund-raising activities.


**1.10 Key Management Personnel:**

(See section 1.10 below)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (2,800.00) is significantly lower than the day's open (2,907.80) and below the previous close (2,891.05).
* It's also below the week's high (2,922.90) but above the week's low (1,851.05).
* The significant negative change (-91.05) and percentage change (-3.15%) indicate a bearish trend.

**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally positive growth over the last five quarters.
* Profit after tax and EPS also show some fluctuation but generally positive growth.

**2.3 Shareholding Analysis:**

* A slight decrease in promoter holding is observed, but it's not alarmingly significant.

**2.4 Corporate Action Summary:**

* No corporate actions impacting the stock price are reported in the data.

**2.5 Volatility and Risk:**

* The data provides CM Daily Volatility (1.85) and CM Annual Volatility (35.34).  These metrics suggest moderate to high volatility.  Further analysis would be needed to assess risk more comprehensively.

**2.6 Key Directors and Contact Info:**

| Name                       | Designation                 |
|----------------------------|-----------------------------|
| Ramesh Juneja              | Chairperson Related To Promoters, Executive Director |
| Vivek Kalra                | Independent Director         |
| Vijaya Sampath             | Independent Director         |
| Bharat Anand               | Independent Director         |
| Tilokchand Punamchand Ostwal | Independent Director         |
| Surendra Lunia             | Independent Director         |
| Satish Kumar Sharma        | Executive Director           |
| Sheetal Arora              | Executive Director-CEO       |
| Rajeev Juneja              | Executive Director-MD        |

**Registrar and Transfer Agent:** KFin Technologies Private Limited

**3. Final Verdict:**

**Hold.**

**Reasoning:**

While the financial performance shows generally positive trends in revenue, profit, and EPS, the recent significant price drop and moderate to high volatility raise concerns. The decrease in promoter holding, although small, adds to the cautious outlook.  The numerous recent announcements related to capital raising and alterations suggest a period of significant corporate activity, making a definitive buy recommendation premature.  More data is needed to assess the long-term impact of these actions.  A "hold" allows for further observation before making a buy or sell decision.

**Conclusion:**

Based on the available data, Mankind Pharma Limited presents a mixed picture.  Positive financial performance is offset by recent price volatility and corporate actions that require further monitoring before a confident buy recommendation can be made.  A "hold" strategy is advised until more information becomes available.
